The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...
IEEE Spectrum on MSN
Why the most accurate glucose monitors are failing some users
In late November Abbott—one of Dexcom’s main competitors— recalled some of its CGMs due to inaccurate low glucose readings.
Sands Capital, an investment management company, released its “Sands Capital Select Growth Strategy” Q3 2025 investor letter.
Morgan Stanley analyst Patrick Wood upgraded the stock to Overweight from Equal Weight on Tuesday, citing a favorable ...
6d
‘A Cause for Candice’: Roc Nation Rallies To Help Beloved Team Member Find Lifesaving Kidney Donor
In 2021, she joined Roc Nation’s office operations team full-time, bringing years of institutional knowledge and loyalty with ...
Adults with type 2 diabetes who used a continuous glucose monitor and wore their sensor for more than 270 days in 1 year had ...
A noninvasive method for measuring blood glucose levels, developed at MIT, could save diabetes patients from having to prick ...
Some FreeStyle Libre 3 glucose sensors made by Abbott Diabetes Care may give incorrect low readings. The devices have been linked to potential deaths.
Stelo by Dexcom is a wearable glucose biosensor that brings continuous glucose monitoring into the consumer wellness space, ...
Millions of people rely on continuous glucose monitors to help manage diabetes. But a new alert from the U.S. Food and Drug ...
MONTREAL--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Québec government for its recent decision to expand coverage of Dexcom Continuous Glucose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback